Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Paritaprevir/r/Ombitasvir + Dasabuvir 8 weeks in HCV-genotype 1b with mild-moderate fibrosis: Results from a Real World Cohort.

Puigvehí M, De Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, De la Vega J, Calleja JL, Carrión JA.

Liver Int. 2018 Aug 30. doi: 10.1111/liv.13950. [Epub ahead of print]

PMID:
30160363
2.

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.

Cuypers L, Pérez AB, Chueca N, Aldamiz-Echevarría T, Alados JC, Martínez-Sapiña AM, Merino D, Pineda JA, Téllez F, Espinosa N, Salméron J, Rivero-Juarez A, Vivancos MJ, Hontañón V, Vandamme AM, García F.

PLoS One. 2018 Jul 25;13(7):e0201268. doi: 10.1371/journal.pone.0201268. eCollection 2018.

3.

Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349].

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, López Miranda J, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego-Durán R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476. doi: 10.1016/j.gastrohep.2018.05.011. English, Spanish. No abstract available.

PMID:
29929828
4.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 7. English, Spanish. Erratum in: Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476.

PMID:
29631866
5.

Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C.

Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M.

J Hepatol. 2018 May;68(5):940-948. doi: 10.1016/j.jhep.2017.12.019. Epub 2017 Dec 28.

PMID:
29288753
6.

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.

Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F; TENOSIMP-B Research Group.

World J Gastroenterol. 2017 Nov 7;23(41):7459-7469. doi: 10.3748/wjg.v23.i41.7459.

7.

Poly(ADP-ribose)polymerases inhibitors prevent early mitochondrial fragmentation and hepatocyte cell death induced by H2O2.

Martín-Guerrero SM, Muñoz-Gámez JA, Carrasco MC, Salmerón J, Martín-Estebané M, Cuadros MA, Navascués J, Martín-Oliva D.

PLoS One. 2017 Oct 26;12(10):e0187130. doi: 10.1371/journal.pone.0187130. eCollection 2017.

8.

Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.

Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J.

World J Gastroenterol. 2017 Jul 7;23(25):4538-4547. doi: 10.3748/wjg.v23.i25.4538.

9.

Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.

López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ, Rodríguez-Muñoz Y, Martín-Vílchez S, García-Buey L, González-Moreno L, Real-Martínez Y, Muñoz de Rueda P, Salmerón J, Vidal-Castiñeira JR, López-Larrea C, Rodrigo L, Moreno-Otero R, Sanz-Cameno P.

PLoS One. 2017 Jul 12;12(7):e0180927. doi: 10.1371/journal.pone.0180927. eCollection 2017.

10.

AA-NAT, MT1 and MT2 Correlates with Cancer Stem-Like Cell Markers in Colorectal Cancer: Study of the Influence of Stage and p53 Status of Tumors.

Casado J, Iñigo-Chaves A, Jiménez-Ruiz SM, Ríos-Arrabal S, Carazo-Gallego Á, González-Puga C, Núñez MI, Ruíz-Extremera Á, Salmerón J, León J.

Int J Mol Sci. 2017 Jun 11;18(6). pii: E1251. doi: 10.3390/ijms18061251.

11.

Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.

Martín-Guerrero SM, León J, Quiles-Perez R, Belmonte L, Martin-Oliva D, Ruiz-Extremera Á, Salmerón J, Muñoz-Gámez JA.

Curr Med Chem. 2017;24(20):2156-2173. doi: 10.2174/0929867324666170316115039. Review.

PMID:
28302009
12.

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.

Fernández Carrillo C, Lens S, Llop E, Pascasio JM, Crespo J, Arenas J, Fernández I, Baliellas C, Carrión JA, de la Mata M, Buti M, Castells L, Albillos A, Romero M, Turnes J, Pons C, Moreno-Planas JM, Moreno-Palomares JJ, Fernández-Rodriguez C, García-Samaniego J, Prieto M, Fernández Bermejo M, Salmerón J, Badia E, Salcedo M, Herrero JI, Granados R, Blé M, Mariño Z, Calleja JL.

Hepatology. 2017 Jun;65(6):1810-1822. doi: 10.1002/hep.29097. Epub 2017 Apr 28.

PMID:
28170112
13.

Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods.

Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-Del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, delCampo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI.

J Clin Microbiol. 2016 Jul;54(7):1933. doi: 10.1128/JCM.01007-16. No abstract available.

14.

[Hepatitis C during pregnancy, vertical transmission and new treatment possibilities].

Muñoz-Gámez JA, Salmerón J, Ruiz-Extremera Á.

Med Clin (Barc). 2016 Dec 2;147(11):499-505. doi: 10.1016/j.medcli.2016.04.003. Epub 2016 May 18. Review. Spanish.

PMID:
27209226
15.

Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.

Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R; Alhambra Spanish Study Group.

World J Gastroenterol. 2015 Aug 14;21(30):9163-74. doi: 10.3748/wjg.v21.i30.9163.

16.

[HEPATOTOXICITY FROM THE CONSUMPTION OF HERBALIST PRODUCTS BY A PAEDIATRIC POPULATION].

Ocete-Hita E, Sameron-Fernández MJ, González Gómez JM, Urrutia Maldonado E, Salmerón Ruiz M, Ruiz-Extremera A, Salmerón J.

Nutr Hosp. 2015 Aug 1;32(2):652-5. doi: 10.3305/nh.2015.32.2.8853. Spanish.

17.

Obesity-related non-alcoholic fatty liver disease (NAFLD): A multifactorial process.

Carazo Á, Salmerón J.

Rev Esp Enferm Dig. 2014 Dec;106(8):501-4. No abstract available.

18.

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods.

Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, del Campo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI.

J Clin Microbiol. 2015 Jan;53(1):219-26. doi: 10.1128/JCM.02093-14. Epub 2014 Nov 5. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1933.

19.

Nonalcoholic steatohepatitis in a patient with ataxia-telangiectasia.

Caballero T, Caba-Molina M, Salmerón J, Gómez-Morales M.

Case Reports Hepatol. 2014;2014:761250. doi: 10.1155/2014/761250. Epub 2014 Jan 6.

20.

Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.

Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, Diago M, Bonet L, Gallego A, García-Samaniego J, Testillano M, Rodríguez M, Castellano G, Gutiérrez ML, Delgado M, Mas A, Romero-Gómez M, Calleja JL, González-Guirado A, Arenas JI, García-Buey L, Andrade R, Gila A; ORIENTE-2 study group.

Eur J Gastroenterol Hepatol. 2015 Jan;27(1):46-54. doi: 10.1097/MEG.0000000000000195.

PMID:
25341057

Supplemental Content

Loading ...
Support Center